

August 10, 2012

The Secretary
Bangalore Stock Exchange Ltd.
Stock Exchange Tower
51, 1st Cross, J C Road
Bangalore 560 027

Dear Sirs

Sub: Un-audited Financial Results of the Company / Limited Review Report
Ref: Clause 41 of Listing Agreement

Scrip Code – Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ


Pursuant to Clause 41 of the Listing Agreement, please find attached the Un-audited Financial Results for the quarter ended June 30, 2012, which have been approved by the Board of Directors of the Company at its meeting held today, August 10, 2012.

The Limited Review Report dated August 10, 2012 issued by the Statutory Auditors in respect of the said Unaudited Financial Results is also attached.

Kindly take the same on record and confirm.

Thanking You,

For **AstraZeneca Pharma India Limited**


Pawan Singh
Vice President - Legal & Secretarial

CC : **Bombay Stock Exchange Limited**
Corporate Relationship Dept., P J Towers, Dalal Street, Fort, Mumbai 400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051

AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial results for the quarter ended 30 June 2012

Part I		Rs in lakhs (except for number of shares)			
Sl No.	Particulars	3 months ended 30/06/2012 (Unaudited)	3 months ended 31/03/2012 (Unaudited)	3 months ended 30/06/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	Income from operations				
	a) Net sales/ income from operations (net of excise duty)	9,126.08	9,168.98	13,748.23	53,127.97
	b) Other operating income	2.79	9.70	6.04	24.05
	Total income from operations (net)	9,128.87	9,178.68	13,754.27	53,152.02
2	Expenses				
	(a) Cost of materials consumed	715.85	1,409.45	2,399.09	7,151.68
	(b) Purchase of stock-in-trade	2,623.54	834.28	3,148.44	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	452.24	2,216.16	(1,391.62)	(1,210.38)
	(d) Employee benefits expense	3,339.55	5,791.09	3,353.62	16,191.24
	(e) Depreciation and amortisation expense	175.14	181.03	172.74	733.86
	(f) Other expenses	3,924.42	3,843.76	3,727.46	16,070.05
	Total expenses	11,230.74	14,275.77	11,409.73	50,859.58
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(2,101.87)	(5,097.09)	2,344.54	2,292.44
4	Other income	783.53	201.41	144.23	633.04
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(1,318.34)	(4,895.68)	2,488.77	2,925.48
6	Finance costs	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,318.34)	(4,895.68)	2,488.77	2,925.48
8	Exceptional items	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(1,318.34)	(4,895.68)	2,488.77	2,925.48
10	Tax expense	(503.74)	(1,595.23)	813.95	948.97
11	Net profit/(loss) from ordinary activities after tax (9-10)	(814.60)	(3,300.45)	1,674.82	1,976.51
12	Extraordinary Item	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(814.60)	(3,300.45)	1,674.82	1,976.51
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				18,428.52
16	Basic and diluted earnings (Rs) per share (not annualised)	(3.26)	(13.20)	6.70	7.91
Part II					
A	Particulars of shareholding				
1	Public shareholding				
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%
B.	Particulars	3 months ended 30/06/2012			
	Investor complaints				
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	2			
	Disposed of during the quarter	2			
	Remaining unresolved at the end of the quarter	Nil			

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 10 August 2012.
- Figures of the preceding 3 months ended 31 March 2012 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Employee benefit expense for the quarter and year ended 31 March 2012 include provision for terminal compensation benefits payable under the voluntary retirement scheme amounting to Rs 1,877.18 lakhs.
- Other income for the quarter ended 30 June 2012 includes an amount of Rs 693.49 lakhs towards compensation receivable for factory land acquired by National Highway Authority of India in the previous year.
- The above statement of financial results has been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the company's website.
- A foreign national was appointed as Whole time Director of the Company during the previous year. The Company had filed an application with the Central Government under the Companies Act, 1956 seeking approval for the appointment of, and remuneration payable to, the said director in the previous year. The application is pending before the Central Government.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Anandh Balasundaram
Managing Director

AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl.no.	Particulars	3 months ended 30/06/2012 (Unaudited)	3 months ended 31/03/2012 (Unaudited)	3 months ended 30/06/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
(Rs in lakhs)					
1	Segment revenue				
	(a) Healthcare	8,327.42	8,303.82	12,947.86	49,977.92
	(b) Others	801.45	874.86	806.41	3,174.10
	Total	9,128.87	9,178.68	13,754.27	53,152.02
	Less: Inter-segment revenue	-	-	-	-
	Net income from operations	9,128.87	9,178.68	13,754.27	53,152.02
2	Segment results				
	Profit/(loss) before tax and interest				
	(a) Healthcare	(2,078.25)	(5,122.57)	2,317.06	2,165.28
	(b) Others	(23.62)	25.48	27.48	127.16
	Total	(2,101.87)	(5,097.09)	2,344.54	2,292.44
	Add: Other income	783.53	201.41	144.23	633.04
	Less: Interest	-	-	-	-
	Total profit/(loss) before tax	(1,318.34)	(4,895.68)	2,488.77	2,925.48
3	Capital employed				
	(a) Healthcare	13,056.25	11,722.25	15,240.58	11,722.25
	(b) Others	619.21	817.67	637.20	817.67
	(c) Unallocated	4,438.47	6,388.60	3,766.00	6,388.60
	Total	18,113.93	18,928.52	19,643.78	18,928.52

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 Figures of the preceding 3 months ended 31 March 2012 are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. Also the figures upto the end of the third quarter were only reviewed and not subjected to audit.

BSR & Co.

(Registered)

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 3980 6000
Fax +91 80 3980 6999

Review report to the Board of Directors of AstraZeneca Pharma India Limited

We have reviewed the accompanying statement of unaudited financial results of AstraZeneca Pharma India Limited ("the Company") for the period ended 30 June 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Without qualifying our opinion, we draw attention to note 7 in the financial results for the quarter ended 30 June 2012 wherein it is stated that a foreign national, was appointed as whole time director during the previous year. The appointment and remuneration payable to the director is subject to the approval of the Central Government. The Company, in the previous year, had filed an application with the central government for said appointment and remuneration payable.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **BSR & Co.**

Chartered Accountants

Firm Registration Number: 101248W



Zubin Shekary
Partner

Membership Number: 48814

Place: Bangalore

Date: 10 August 2012